Version 2024

2024 ICD-10-CM Diagnosis Code C81.28

Mixed cellularity Hodgkin lymphoma, lymph nodes of multiple sites

ICD-10-CM Code:: C81.28
ICD-10 Code for:: Mixed cellularity Hodgkin lymphoma, lymph nodes mult site
Is Billable?: Yes - Valid for Submission
Chronic Condition Indicator: ^[1]: Chronic
Code Navigator:

Code Information
Approximate Synonyms
Clinical Classification
Tabular List of Diseases and Injuries
Diagnostic Related Groups Mapping
Convert to ICD-9 Code
Patient Education
Other Codes Used Similar Conditions
Code History

Code Classification

Neoplasms
(C00–D49)
- Malignant neoplasms of lymphoid, hematopoietic and related tissue
  (C81-C96)
  - Hodgkin lymphoma
    (C81)

C81.28 is a billable diagnosis code used to specify a medical diagnosis of mixed cellularity hodgkin lymphoma, lymph nodes of multiple sites. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2023 through September 30, 2024.

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

Hodgkin's disease, mixed cellularity
Hodgkin's disease, mixed cellularity of lymph nodes of multiple sites

Clinical Classification

Clinical Category is Hodgkin lymphoma
CCSR Category Code: NEO057
Inpatient Default CCSR: Y - Yes, default inpatient assignment for principal diagnosis or first-listed diagnosis.
Outpatient Default CCSR: Y - Yes, default outpatient assignment for principal diagnosis or first-listed diagnosis.

C81.28 is grouped with Diagnostic Related Groups - MS-DRG Mapping

Diagnostic Related Groups (DRGs) are a classification system used to group together diagnosis codes for the purpose of reimbursement and healthcare management. DRGs are used to standardize the way hospitals and other providers are paid for inpatient services. In this system patients are grouped together based on their principal diagnosis in areas referred to as Major Diagnostic Categories (MDC). Once a patient is assigned a particular diagnostic category, providers receive a predetermined payment rate for the services rendered. This reimbursement rate is often fixed and is meant to cover the cost of care for that patient. Reimbursement is also affected by the relative weight of a diagnostic related group based on the severity of a patient's illness and the associated cost of care during hospitalization.

Diagnostic related groups encourage healthcare providers to focus on quality and efficiency in patient care while managing costs effectively. The diagnosis code is present in the following groups for version MS-DRG V41.0 applicable from 10/01/2023 through 09/30/2024.

MS-DRG	MS-DRG Title	MCD	Relative Weight
820	LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITH MCC	17	6.0467
821	LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITH CC	17	2.2321
822	LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITHOUT CC/MCC	17	1.2388

The relative weight of a diagnostic related group determines the reimbursement rate based on the severity of a patient's illness and the associated cost of care during hospitalization.

Convert C81.28 to ICD-9-CM

ICD-9-CM Code: 201.68 - Hodgkins mix cell mult

Patient Education

Adult Hodgkin Lymphoma Summary

Learn about adult hodgkin lymphoma risk factors, symptoms, tests to diagnose, factors affecting prognosis, staging, and treatment.
[Learn More in MedlinePlus]

Lymphoma-Patient Version

Learn about Hodgkin lymphoma risk factors, symptoms, tests to diagnose, factors affecting prognosis, staging, and treatment.
[Learn More in MedlinePlus]

Other ICD-10-CM Codes Commonly Used for Similar Conditions

Filter related codes list:

C81 Hodgkin lymphoma.
C81.0 Nodular lymphocyte predominant Hodgkin lymphoma.
C81.00 Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site.
C81.01 Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck.
C81.02 Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes.
C81.03 Nodular lymphocyte predominant Hodgkin lymphoma, intra-abdominal lymph nodes.
C81.04 Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb.
C81.05 Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower limb.
C81.06 Nodular lymphocyte predominant Hodgkin lymphoma, intrapelvic lymph nodes.
C81.07 Nodular lymphocyte predominant Hodgkin lymphoma, spleen.
C81.08 Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of multiple sites.
C81.09 Nodular lymphocyte predominant Hodgkin lymphoma, extranodal and solid organ sites.
C81.1 Nodular sclerosis Hodgkin lymphoma.
C81.10 Nodular sclerosis Hodgkin lymphoma, unspecified site.
C81.11 Nodular sclerosis Hodgkin lymphoma, lymph nodes of head, face, and neck.
C81.12 Nodular sclerosis Hodgkin lymphoma, intrathoracic lymph nodes.
C81.13 Nodular sclerosis Hodgkin lymphoma, intra-abdominal lymph nodes.
C81.14 Nodular sclerosis Hodgkin lymphoma, lymph nodes of axilla and upper limb.
C81.15 Nodular sclerosis Hodgkin lymphoma, lymph nodes of inguinal region and lower limb.
C81.16 Nodular sclerosis Hodgkin lymphoma, intrapelvic lymph nodes.
C81.17 Nodular sclerosis Hodgkin lymphoma, spleen.
C81.18 Nodular sclerosis Hodgkin lymphoma, lymph nodes of multiple sites.
C81.19 Nodular sclerosis Hodgkin lymphoma, extranodal and solid organ sites.
C81.2 Mixed cellularity Hodgkin lymphoma.
C81.20 Mixed cellularity Hodgkin lymphoma, unspecified site.
C81.21 Mixed cellularity Hodgkin lymphoma, lymph nodes of head, face, and neck.
C81.22 Mixed cellularity Hodgkin lymphoma, intrathoracic lymph nodes.
C81.23 Mixed cellularity Hodgkin lymphoma, intra-abdominal lymph nodes.
C81.24 Mixed cellularity Hodgkin lymphoma, lymph nodes of axilla and upper limb.
C81.25 Mixed cellularity Hodgkin lymphoma, lymph nodes of inguinal region and lower limb.
C81.26 Mixed cellularity Hodgkin lymphoma, intrapelvic lymph nodes.
C81.27 Mixed cellularity Hodgkin lymphoma, spleen.
C81.29 Mixed cellularity Hodgkin lymphoma, extranodal and solid organ sites.
C81.3 Lymphocyte depleted Hodgkin lymphoma.
C81.30 Lymphocyte depleted Hodgkin lymphoma, unspecified site.
C81.31 Lymphocyte depleted Hodgkin lymphoma, lymph nodes of head, face, and neck.
C81.32 Lymphocyte depleted Hodgkin lymphoma, intrathoracic lymph nodes.
C81.33 Lymphocyte depleted Hodgkin lymphoma, intra-abdominal lymph nodes.
C81.34 Lymphocyte depleted Hodgkin lymphoma, lymph nodes of axilla and upper limb.
C81.35 Lymphocyte depleted Hodgkin lymphoma, lymph nodes of inguinal region and lower limb.
C81.36 Lymphocyte depleted Hodgkin lymphoma, intrapelvic lymph nodes.
C81.37 Lymphocyte depleted Hodgkin lymphoma, spleen.
C81.38 Lymphocyte depleted Hodgkin lymphoma, lymph nodes of multiple sites.
C81.39 Lymphocyte depleted Hodgkin lymphoma, extranodal and solid organ sites.
C81.4 Lymphocyte-rich Hodgkin lymphoma.
C81.40 Lymphocyte-rich Hodgkin lymphoma, unspecified site.
C81.41 Lymphocyte-rich Hodgkin lymphoma, lymph nodes of head, face, and neck.
C81.42 Lymphocyte-rich Hodgkin lymphoma, intrathoracic lymph nodes.
C81.43 Lymphocyte-rich Hodgkin lymphoma, intra-abdominal lymph nodes.
C81.44 Lymphocyte-rich Hodgkin lymphoma, lymph nodes of axilla and upper limb.
C81.45 Lymphocyte-rich Hodgkin lymphoma, lymph nodes of inguinal region and lower limb.

Code History

FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
The condition places limitations on self-care, independent living, and social interactions.